vs
Side-by-side financial comparison of Sight Sciences, Inc. (SGHT) and TRANSACT TECHNOLOGIES INC (TACT). Click either name above to swap in a different company.
Sight Sciences, Inc. is the larger business by last-quarter revenue ($20.4M vs $11.5M, roughly 1.8× TRANSACT TECHNOLOGIES INC). On growth, TRANSACT TECHNOLOGIES INC posted the faster year-over-year revenue change (11.9% vs 6.9%). TRANSACT TECHNOLOGIES INC produced more free cash flow last quarter ($589.0K vs $-2.0M). Over the past eight quarters, TRANSACT TECHNOLOGIES INC's revenue compounded faster (3.5% CAGR vs 2.9%).
Sight Sciences, Inc. is a commercial-stage medical technology company focused on developing and commercializing innovative products for treating common eye conditions including glaucoma and dry eye disease. It offers minimally invasive surgical devices and non-surgical care solutions, primarily serving ophthalmology clinicians and patients across the United States.
Roper Technologies, Inc. is a holding company that owns companies in the technology sector.
SGHT vs TACT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $20.4M | $11.5M |
| Net Profit | $-4.2M | — |
| Gross Margin | 87.3% | 47.6% |
| Operating Margin | -18.0% | -10.1% |
| Net Margin | -20.4% | — |
| Revenue YoY | 6.9% | 11.9% |
| Net Profit YoY | 64.9% | — |
| EPS (diluted) | $-0.07 | $-0.11 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $20.4M | $11.5M | ||
| Q3 25 | $19.9M | $13.2M | ||
| Q2 25 | $19.6M | $13.8M | ||
| Q1 25 | $17.5M | $13.1M | ||
| Q4 24 | $19.1M | $10.2M | ||
| Q3 24 | $20.2M | $10.9M | ||
| Q2 24 | $21.4M | $11.6M | ||
| Q1 24 | $19.3M | $10.7M |
| Q4 25 | $-4.2M | — | ||
| Q3 25 | $-8.2M | $15.0K | ||
| Q2 25 | $-11.9M | $-143.0K | ||
| Q1 25 | $-14.2M | $19.0K | ||
| Q4 24 | $-11.8M | — | ||
| Q3 24 | $-11.1M | $-551.0K | ||
| Q2 24 | $-12.3M | $-319.0K | ||
| Q1 24 | $-16.3M | $-1.0M |
| Q4 25 | 87.3% | 47.6% | ||
| Q3 25 | 86.4% | 49.8% | ||
| Q2 25 | 84.8% | 48.2% | ||
| Q1 25 | 86.2% | 48.7% | ||
| Q4 24 | 86.8% | 44.2% | ||
| Q3 24 | 83.9% | 48.1% | ||
| Q2 24 | 85.8% | 52.7% | ||
| Q1 24 | 85.5% | 52.6% |
| Q4 25 | -18.0% | -10.1% | ||
| Q3 25 | -39.7% | 0.1% | ||
| Q2 25 | -59.6% | -1.9% | ||
| Q1 25 | -79.2% | -0.1% | ||
| Q4 24 | -62.5% | -10.3% | ||
| Q3 24 | -55.7% | -7.7% | ||
| Q2 24 | -59.2% | -3.8% | ||
| Q1 24 | -76.4% | -12.2% |
| Q4 25 | -20.4% | — | ||
| Q3 25 | -41.0% | 0.1% | ||
| Q2 25 | -61.0% | -1.0% | ||
| Q1 25 | -80.8% | 0.1% | ||
| Q4 24 | -62.1% | — | ||
| Q3 24 | -54.9% | -5.1% | ||
| Q2 24 | -57.7% | -2.8% | ||
| Q1 24 | -84.4% | -9.7% |
| Q4 25 | $-0.07 | $-0.11 | ||
| Q3 25 | $-0.16 | $0.00 | ||
| Q2 25 | $-0.23 | $-0.01 | ||
| Q1 25 | $-0.28 | $0.00 | ||
| Q4 24 | $-0.23 | $-0.80 | ||
| Q3 24 | $-0.22 | $-0.06 | ||
| Q2 24 | $-0.25 | $-0.03 | ||
| Q1 24 | $-0.33 | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $92.0M | $20.4M |
| Total DebtLower is stronger | $42.4M | — |
| Stockholders' EquityBook value | $63.9M | $31.1M |
| Total Assets | $115.3M | $44.8M |
| Debt / EquityLower = less leverage | 0.66× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $92.0M | $20.4M | ||
| Q3 25 | $92.4M | $20.0M | ||
| Q2 25 | $101.5M | $17.7M | ||
| Q1 25 | $108.8M | $14.2M | ||
| Q4 24 | $120.4M | $14.4M | ||
| Q3 24 | $118.6M | $11.3M | ||
| Q2 24 | $118.2M | $11.1M | ||
| Q1 24 | $127.3M | $10.6M |
| Q4 25 | $42.4M | — | ||
| Q3 25 | $42.4M | — | ||
| Q2 25 | $42.4M | — | ||
| Q1 25 | $42.4M | — | ||
| Q4 24 | $40.0M | — | ||
| Q3 24 | $37.1M | — | ||
| Q2 24 | $35.0M | — | ||
| Q1 24 | $35.0M | — |
| Q4 25 | $63.9M | $31.1M | ||
| Q3 25 | $64.3M | $31.8M | ||
| Q2 25 | $70.0M | $31.3M | ||
| Q1 25 | $77.6M | $30.9M | ||
| Q4 24 | $87.5M | $30.6M | ||
| Q3 24 | $95.0M | $38.4M | ||
| Q2 24 | $101.6M | $38.5M | ||
| Q1 24 | $109.2M | $38.6M |
| Q4 25 | $115.3M | $44.8M | ||
| Q3 25 | $116.3M | $45.0M | ||
| Q2 25 | $122.0M | $44.5M | ||
| Q1 25 | $129.7M | $44.2M | ||
| Q4 24 | $142.8M | $44.0M | ||
| Q3 24 | $143.6M | $50.5M | ||
| Q2 24 | $149.7M | $50.4M | ||
| Q1 24 | $155.6M | $51.9M |
| Q4 25 | 0.66× | — | ||
| Q3 25 | 0.66× | — | ||
| Q2 25 | 0.61× | — | ||
| Q1 25 | 0.55× | — | ||
| Q4 24 | 0.46× | — | ||
| Q3 24 | 0.39× | — | ||
| Q2 24 | 0.34× | — | ||
| Q1 24 | 0.32× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.8M | $609.0K |
| Free Cash FlowOCF − Capex | $-2.0M | $589.0K |
| FCF MarginFCF / Revenue | -9.7% | 5.1% |
| Capex IntensityCapex / Revenue | 0.8% | 0.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $7.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-1.8M | $609.0K | ||
| Q3 25 | $-8.7M | $3.6M | ||
| Q2 25 | $-7.5M | $3.6M | ||
| Q1 25 | $-11.6M | $-161.0K | ||
| Q4 24 | $-3.5M | $2.4M | ||
| Q3 24 | $362.0K | $327.0K | ||
| Q2 24 | $-9.5M | $636.0K | ||
| Q1 24 | $-9.8M | $-1.5M |
| Q4 25 | $-2.0M | $589.0K | ||
| Q3 25 | $-8.9M | $3.6M | ||
| Q2 25 | $-7.8M | $3.6M | ||
| Q1 25 | — | $-171.0K | ||
| Q4 24 | $-3.6M | $2.4M | ||
| Q3 24 | $311.0K | $259.0K | ||
| Q2 24 | $-9.5M | $499.0K | ||
| Q1 24 | $-9.9M | $-1.6M |
| Q4 25 | -9.7% | 5.1% | ||
| Q3 25 | -44.7% | 27.1% | ||
| Q2 25 | -39.6% | 25.9% | ||
| Q1 25 | — | -1.3% | ||
| Q4 24 | -18.9% | 23.2% | ||
| Q3 24 | 1.5% | 2.4% | ||
| Q2 24 | -44.7% | 4.3% | ||
| Q1 24 | -51.4% | -14.9% |
| Q4 25 | 0.8% | 0.2% | ||
| Q3 25 | 0.9% | 0.5% | ||
| Q2 25 | 1.1% | 0.1% | ||
| Q1 25 | 0.0% | 0.1% | ||
| Q4 24 | 0.7% | 0.1% | ||
| Q3 24 | 0.3% | 0.6% | ||
| Q2 24 | 0.4% | 1.2% | ||
| Q1 24 | 0.6% | 1.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | 242.00× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -8.47× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
SGHT
| Surgical Glaucoma | $19.7M | 96% |
| Other | $724.0K | 4% |
TACT
Segment breakdown not available.
